In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus ...

Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.

Vaccine development remains central to reducing incident HIV globally, particularly where long-acting PrEP access is limited, with therapeutic and preventive approaches advancing in parallel.

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Since the human immunodeficiency virus (HIV) was identified in 1983, roughly 91.4 million people around the world have contracted the virus and an additional 44.1 million have died from related causes ...